Literature DB >> 12130722

Effects of antidepressants in rats trained to discriminate centrally administered isoproterenol.

Alicia M Crissman1, James M O'Donnell.   

Abstract

Previous work has shown that the discriminative stimulus effects of centrally administered isoproterenol are mediated primarily via beta1-adrenergic receptors. In the present study, this model was used to investigate the ability of antidepressant drugs displaying various pharmacological profiles to stimulate beta1-adrenergic receptors in vivo; this was assessed by determining whether they substituted for the discriminative stimulus effects of isoproterenol. Rats were trained to discriminate centrally administered isoproterenol (10 microg i.c.v.) from artificial cerebral spinal fluid using a water-reinforced, two-lever operant task (fixed ratio 10 schedule). After acquisition of the discrimination, drugs were tested for substitution (i.p.). The tricyclic antidepressants protriptyline and desipramine, the norepinephrine uptake inhibitor nisoxetine, the monoamine oxidase inhibitor phenelzine, and the atypical antidepressants bupropion, mirtazapine, and venlafaxine all produced greater than 90% isoproterenol-appropriate responding. The serotonin uptake inhibitor fluoxetine, the atypical antidepressants buspirone and trazodone, and the novel, putative antidepressants N(G)-nitro-L-arginine and N-acetyl-L-tryptophan 3,5-bis benzyl ester failed to substitute for isoproterenol at the dose ranges tested. Antagonism studies carried out with betaxolol for those drugs that fully generalized to isoproterenol's cue verified mediation by beta1-adrenergic receptors. The present results indicate that drugs with noradrenergic activity generalize to isoproterenol's discriminative stimulus. Although this suggests a role for central beta1-adrenergic receptors in the mechanism of action of certain antidepressant drugs, it does not seem that stimulation of these receptors is an effect shared by antidepressants from all pharmacological classes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12130722     DOI: 10.1124/jpet.102.034686

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  Antagonism of the antidepressant-like effects of clenbuterol by central administration of beta-adrenergic antagonists in rats.

Authors:  Han-Ting Zhang; Ying Huang; James M O'Donnell
Journal:  Psychopharmacology (Berl)       Date:  2003-07-25       Impact factor: 4.530

2.  Interaction between the antidepressant-like behavioral effects of beta adrenergic agonists and the cyclic AMP PDE inhibitor rolipram in rats.

Authors:  Han-Ting Zhang; Ying Huang; Kathleen Mishler; Sandra C Roerig; James M O'Donnell
Journal:  Psychopharmacology (Berl)       Date:  2005-09-29       Impact factor: 4.530

3.  The role of dopaminergic transmission through D1-like and D2-like receptors in amphetamine-induced rat ultrasonic vocalizations.

Authors:  Jennifer M Wright; May R S Dobosiewicz; Paul B S Clarke
Journal:  Psychopharmacology (Berl)       Date:  2012-09-28       Impact factor: 4.530

4.  Postsynaptic alpha-2 adrenergic receptors are critical for the antidepressant-like effects of desipramine on behavior.

Authors:  Han-Ting Zhang; Lisa R Whisler; Ying Huang; Yang Xiang; James M O'Donnell
Journal:  Neuropsychopharmacology       Date:  2008-10-15       Impact factor: 7.853

5.  Association of changes in norepinephrine and serotonin transporter expression with the long-term behavioral effects of antidepressant drugs.

Authors:  Zaorui Zhao; Han-Ting Zhang; Elianna Bootzin; Mark J Millan; James M O'Donnell
Journal:  Neuropsychopharmacology       Date:  2008-10-15       Impact factor: 7.853

6.  Discriminative stimulus properties of the atypical antidepressant, mirtazapine, in rats: a pharmacological characterization.

Authors:  Anne Dekeyne; Mark J Millan
Journal:  Psychopharmacology (Berl)       Date:  2008-08-16       Impact factor: 4.530

7.  Trazodone alleviates both dyskinesia and psychosis in the parkinsonian marmoset model of Parkinson's disease.

Authors:  Adjia Hamadjida; Stephen G Nuara; Jim C Gourdon; Philippe Huot
Journal:  J Neural Transm (Vienna)       Date:  2017-12-15       Impact factor: 3.575

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.